Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non-cash Items (2020 - 2023)

Mirum Pharmaceuticals (MIRM) has 4 years of Non-cash Items data on record, last reported at $19.6 million in Q4 2023.

  • For Q4 2023, Non-cash Items fell 62.05% year-over-year to $19.6 million; the TTM value through Dec 2023 reached $19.6 million, down 62.05%, while the annual FY2023 figure was $19.6 million, 62.05% down from the prior year.
  • Non-cash Items reached $19.6 million in Q4 2023 per MIRM's latest filing, down from $20.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $63.4 million in Q3 2022 and bottomed at $16.5 million in Q2 2023.
  • Average Non-cash Items over 4 years is $41.1 million, with a median of $44.4 million recorded in 2020.
  • Peak YoY movement for Non-cash Items: surged 58.24% in 2022, then crashed 68.44% in 2023.
  • A 4-year view of Non-cash Items shows it stood at $40.6 million in 2020, then fell by 19.67% to $32.6 million in 2021, then surged by 58.24% to $51.6 million in 2022, then plummeted by 62.05% to $19.6 million in 2023.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $19.6 million in Q4 2023, $20.0 million in Q3 2023, and $16.5 million in Q2 2023.